期刊文献+

人卵巢癌基因治疗的几种方案 被引量:1

Progress in Gene Therapy of Ovarian Cancer
下载PDF
导出
摘要 卵巢癌的基因治疗业已取得了很大的进展。重组回旋病毒、腺病毒或非病毒脂质体有可能作为安全、有效的媒介物质 ;分子化学疗法、突变补偿、免疫增强和耐药性变化等基因治疗方法不断得到了发展和完善。部分治疗方案 (特别是单纯疱疹病毒胸腺嘧啶脱氧核苷激酶方案等 ) Considerable progess has been made in gene therapy of ovarian cancer.Recombinant retrovirus,adenovirus and nonviral liposome have been developed for the candidates of vectors.Various gene therapies of ovarian cancer,e.g,molecular chemotherapy,mutation compensation,immunopotentiation and multi drug resistance,are being kept advances and perfects.Some of the gene therapy protocols,including herpes simplex virus thymidine kinase based,adoptive immunotherapy based,active immunotherapy based and multi drug resistance gene based protocols have been on trail or clinical application.
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2001年第5期273-275,共3页 Journal of Practical Obstetrics and Gynecology
关键词 卵巢癌 基因治疗 HSV-TK 分子化学疗法 突变补偿 Ovarian cancer Gene therapy HSV TK
  • 相关文献

参考文献4

二级参考文献16

  • 1徐丛剑,许秀兰,张惜阴,郭忠,丰有吉,金志军,曹斌融,顾健人.逆转录病毒介导Ⅰ型单纯疱疹病毒胸腺嘧啶核苷激酶基因转导卵巢癌细胞的研究[J].中华妇产科杂志,1996,31(11):664-666. 被引量:9
  • 2成军.基因治疗[M].北京:学苑出版社,1992.102-134.
  • 3徐丛剑 金志军 等.人卵巢癌裸鼠腹腔及网膜常位移植[J].现代妇产科进展,1997,6:111-113.
  • 4许凯黎,中华医学杂志,1995年,75卷,233页
  • 5张国玲,中华妇产科杂志,1994年,29卷,401页
  • 6许凯黎,上海医学,1992年,15卷,461页
  • 7徐丛剑,现代妇产科进展,1997年,6卷,111页
  • 8徐丛剑,中华妇产科杂志,1997年,12卷,709页
  • 9Tong X W,Gynecol Oncol,1996年,61卷,175页
  • 10徐丛剑,中华妇产科杂志,1996年,31卷,664页

共引文献11

同被引文献19

  • 1Kastan MB, Canman CE, Leonard C J, P53, cell-cycle control and apoptosis-implications for cancer. Cancer Metastasis Rev, 1995,14 ( 1 ) : 3 - 15,.
  • 2Randrianarison V, Marot D, Foray N, et al. BRCA 1 carries tumor suppressor activity distinct from that of p53 and p21, Cancer Gene Ther, 2001,8(10) :759 -770.
  • 3Alvarez RD, Gomez-Navarro J, Wang M, et al. Adenoviral-mediated suicide gene therapy for ovarian cancer. Mol Ther, 2000,2(5) : 524 - 530.
  • 4Tai YT, Strobel T, Kufe D, et al. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res, 1999,59(9):2121 - 2126.
  • 5Janicek MF, Sevin BU ,Nguyen HN, et al. Combination anti-gene therapy targeting c-myc and p53 in ovarian cancer cell lines. Genecol Oncol, 1995,59(1 ):87 - 92.
  • 6Sabet MK,Funato T,Fodstad O,et al.Suppression of tile nepotistic in vivo by an anti-ras ribzyome.Cancer Res, 1994,54(4) :900 - 902.
  • 7Deshane J, Grim J, Loechel S, et al. Intracellular antibody against erbB-2 mediates targeted tumor cell eradication by apoptosis. Cancer Gene Therapy, 1996,3(2) :89 - 98.
  • 8Hortobagyi GN,Heno NT,Xia W,et al. Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial.J Clin 0ncol,2001,19(14):3422- 3433.
  • 9Freedman RS, Platsoucas CD. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat Res, 1996,82(1) : 115 - 146.
  • 10Heike Y, Kasono K, Kunisaki C, et al. Overcoming multi-drug resistance using an intracellular anti-MDR1 sFv. Int J Cancer, 2001,92 (1) : 115 - 122.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部